Scarica l'app Stockscreener
13.40
2.72%
0.335
Precedente Chiudi:
$13.06
Aprire:
$13.26
Volume 24 ore:
228.85K
Relative Volume:
1.42
Capitalizzazione di mercato:
$453.42M
Reddito:
$59,000
Utile/perdita netta:
$-21.81M
Rapporto P/E:
-1.2235
EPS:
-10.9518
Flusso di cassa netto:
$-18.07M
1 W Prestazione:
+3.55%
1M Prestazione:
-14.96%
6M Prestazione:
-11.54%
1 anno Prestazione:
+37.22%
Intervallo 1D:
$12.70
$13.46
Intervallo di 1 settimana:
$11.54
$13.46
Portata 52W:
$9.70
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Nome
Benitec Biopharma Inc
Settore
Industria
Telefono
(510) 780-0819
Indirizzo
3940 TRUST WAY, HAYWARD, CA
Confronta BNTC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
13.39 | 446.30M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.17 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.87 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.00 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
903.20 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.54 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-09-12 | Iniziato | Guggenheim | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Piper Sandler | Overweight |
| 2020-10-05 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-02-26 | Downgrade | Maxim Group | Buy → Hold |
| 2015-12-31 | Reiterato | Maxim Group | Buy |
| 2015-09-16 | Reiterato | Maxim Group | Buy |
Mostra tutto
Benitec Biopharma Inc Borsa (BNTC) Ultime notizie
Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know - Nasdaq
Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) - Yahoo Finance
Benitec Biopharma shareholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria
Benitec Biopharma shareholders approve all proposals at annual meeting - Investing.com
Benitec Biopharma Concludes 2025 Annual Stockholders Meeting - TipRanks
Price-Driven Insight from (BNTC) for Rule-Based Strategy - news.stocktradersdaily.com
Can Benitec Biopharma Inc. stock continue upward trendJuly 2025 Momentum & AI Enhanced Execution Alerts - Newser
Risk Check: Can Benitec Biopharma Inc. stock double in next 5 years - BỘ NỘI VỤ
Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others - AOL.com
Why Benitec Biopharma Inc. stock could be next big winner2025 Key Lessons & Weekly Momentum Picks - moha.gov.vn
Can Benitec Biopharma Inc. stock double in next 5 yearsJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - moha.gov.vn
HC Wainwright Has Optimistic Outlook of BNTC FY2026 Earnings - MarketBeat
What is HC Wainwright's Estimate for BNTC Q2 Earnings? - MarketBeat
Q2 Earnings Estimate for BNTC Issued By HC Wainwright - Defense World
BNTC Analyst Rating Maintained but Price Target Lowered to $32 b - GuruFocus
HC Wainwright & Co. Maintains Benitec Biopharma (BNTC) Buy Recommendation - MSN
Benitec Biopharma (NASDAQ:BNTC) Rating Increased to Hold at Wall Street Zen - Defense World
Benitec Biopharma Shares Surge 20% After FDA Grants Fast Track Status for OPMD Gene Therapy - MSN
(BNTC) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Is Benitec Biopharma Inc. stock a smart buy before Fed meetingWeekly Trade Summary & Low Risk Growth Stock Ideas - newser.com
[Form 4] Benitec Biopharma Inc. Insider Trading Activity - Stock Titan
Pattern recognition hints at Benitec Biopharma Inc. upsideJuly 2025 Final Week & Risk Adjusted Buy and Sell Alerts - newser.com
Can Benitec Biopharma Inc. stock sustain market leadershipEarnings Miss & Risk Managed Trade Strategies - newser.com
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Is Benitec Biopharma Inc. a candidate for recovery play2025 Top Gainers & Trade Opportunity Analysis - newser.com
Is Benitec Biopharma Inc. stock affected by interest rate hikesLong Setup & Reliable Intraday Trade Alerts - newser.com
Strategies to average down on Benitec Biopharma Inc.July 2025 Recap & Technical Buy Zone Confirmations - newser.com
Benitec Biopharma Inc. recovery potential after sell off2025 Buyback Activity & Risk Controlled Stock Alerts - newser.com
Is Benitec Biopharma Inc. stock attractive for growth ETFs2025 Market WrapUp & Risk Controlled Daily Plans - newser.com
Can a trend reversal in Benitec Biopharma Inc. lead to recoveryProfit Target & Community Consensus Trade Alerts - newser.com
Citizens reiterates Market Outperform rating on Benitec BioPharma stock By Investing.com - Investing.com Canada
Real time social sentiment graph for Benitec Biopharma Inc.2025 Market Overview & Fast Moving Market Watchlists - newser.com
Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment - Finviz
Benitec Biopharma Reports Increased Quarterly Loss Amid Rising Expenses - MSN
Hedge funds investors have a lot riding on Benitec Biopharma Inc. (NASDAQ:BNTC) with 37% ownership - Yahoo Finance
Citizens reiterates Market Outperform rating on Benitec BioPharma stock - Investing.com India
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid sector headwinds - Investing.com Nigeria
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid sector headwinds By Investing.com - Investing.com South Africa
Benitec Biopharma Inc Azioni (BNTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Benitec Biopharma Inc Azioni (BNTC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 31 '25 |
Buy |
12.83 |
16,497 |
211,736 |
8,807,805 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 26 '25 |
Buy |
13.00 |
900,000 |
11,700,000 |
8,793,245 |
| BUCHI J KEVIN | Director |
Feb 27 '25 |
Option Exercise |
3.86 |
51,813 |
199,998 |
103,910 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '24 |
Buy |
10.98 |
27,502 |
301,972 |
7,981,725 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 24 '24 |
Buy |
11.25 |
20,018 |
225,202 |
7,999,455 |
0.77%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):